Trial Profile

A Randomized, Placebo-Controlled, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Dec 2024 According to a Caliway Biopharmaceuticals media release, Primary endpoint (Participants with at least 1-grade improvement reported by Investigator using the Clinician-Reported Abdominal Fat Rating Scale)has been met.
11 Dec 2024 According to a Caliway Biopharmaceuticals media release,announced the study results of the CBL-514 Phase 2b study for subcutaneous fat reduction which met all the primary and secondary efficacy endpoints in the FAS (Full analysis set) and PP (Per-protocol) population analysis.
11 Dec 2024 Results published in the Caliway Biopharmaceuticals media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com